ICAAC, IDWeek, and the European AIDS Conference 2015*

September 17-October 24, 2015; San Diego, California; Barcelona, Spain
Review the clinical impact of new HIV-related data presented at 3 scientific meetings in the fall of 2015: ICAAC, IDWeek, and the European AIDS Conference. This program includes Capsule Summaries, downloadable slidesets, and an expert analysis text module.

Fall 2015 HIV Update


In this pilot study, all 20 patients experienced virologic suppression (HIV-1 RNA < 50 copies/mL) by Week 8 of initial dolutegravir plus lamivudine therapy and maintained virologic suppression through Week 24 of treatment; there were no serious adverse effects.

Released: October 23, 2015

High baseline HIV-1 RNA (≥ 100,000 copies/mL) or low CD4+ cell count (< 200 cells/mm3) were associated with a lower proportion of BMS-663068-treated patients with HIV-1 RNA < 50 copies/mL at Week 48

Released: October 23, 2015

Although rare, virologic failure was associated with emergence of integrase gene mutations.

Released: October 27, 2015

Secondary measures of cognitive function and patient-reported cognitive outcomes also did not differ according to treatment allocation.

Released: October 26, 2015

In this randomized phase III trial, the switch to dolutegravir/abacavir/lamivudine was associated with a higher frequency of treatment discontinuation due to adverse events but higher treatment satisfaction score.

Released: October 22, 2015

Rates of osteoporosis in the BMD substudy population and fracture in the overall START population did not differ statistically between groups.

Released: October 27, 2015

Switching to the TAF-containing regimen improved renal and bone markers, but increased lipids.

Released: October 21, 2015

Switch associated with reduced pill burden, greater treatment satisfaction, improvement in urinary markers of renal function, but more frequent AEs.

Released: October 26, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Bristol-Myers Squibb
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?